Refractory or Relapsed RMS and Soft Tissue Sarcomas
Conditions
Brief summary
The purpose of this study is to determine the Everolimus aim response in children and adolescents with refractory or relapsed Rhabdomyosarcoma and other soft tissue sarcomas
Interventions
DRUGEverolimus
Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
Sponsors
Sidnei Epelman
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
* Rhabdomyosarcoma and other soft tissue sarcoma histological confirmation. * No option of known curative treatment, neither approved treatment that increases survival with adequate quality of life. * Karnofsky scale ≥ 50 for patients over 16 years and Lansky scale ≥ 50 for patients under 16 years old. * Subjects shouldn't have received antineoplasic therapy \< 4 weeks before study treatment initiation. * Adequate hematological function: neutrophil count \> 1.500/mm³ and hemoglobin \> 8.0 mg/dL. * Adequate renal function, as defined below: Age Maximum serum creatinine (mg/dL) 0 - 29 days 0,4 - 0,7 1 month - 3 years 0,7 4 - 7 years 0,8 8 - 10 years 0,9 11 - 12 years 1,0 13 - 17 years 1,2 ≥ 18 years 1,3 * Adequate hepatic function: total bilirubin ≤ 1.5 x ULN. * Patient and/or legal responsible must sign ICF. * Life expectation \> 8 weeks. * Measurable disease, according to RECIST criteria. * For female patients of childbearing age: presence of a negative pregnancy test within 7 days prior to day 0. * The patient agrees to use effective contraception if procreative potential exists. Use of reliable means of contraception (e.g. hormonal contraceptive, patch, vaginal ring, intrauterine device, physical barrier, abstinence)for subjects of reproductive potential (male and female) is required during study treatment and for 3 months following last dose of study drug.
Exclusion criteria
* History of myocardial infarction, angina and cerebrovascular accident related to atherosclerosis. * Pulmonary disorder(e.g. FEV1 ou DLCO ≤ 70% from expected). * Significant hematologic or hepatic abnormality (transaminases levels \> 2.5 x ULN or serum bilirubin \> 1.5 x ULN, hemoglobin \< 8 g/dL, platelets \< 100.000/mm³, ANC \< 1.500/mm³. * Has other existing serious medical conditions that could adversely affect the ability of the patient to be treated in accordance with the protocol. * Any condition, therapy, or medical condition, which, in the opinion of the attending physician could represent a risk for the patient or adversely affect the study objectives. * If female, is pregnant or lactating. * Active infection at the moment of recruitment. * Previous history of organ transplantation. * Recent surgery \< 2 months before entering study. * Concomitant antineoplasic therapy. * Patient received more than one rescue treatment, previously. * Previous treatment with mTor inhibitors (ex: sirolimus, temsirolimus, everolimus). * Use of investigational drug \< 30 days before entering study. * Non-controlled hyperlipidaemia: serum cholesterol (fasting) \> 300 mg/dL or 7,75 mmol/L and triglycerides (fasting) \> 2,5 x ULN. * Non-controlled Diabetes Mellitus defined as: glycemia (fasting) \> 1,5 x ULN. * Patient with hemorrhagic disorder or using oral anti-vitamin K (except Warfarin in low doses). * Patient with HIV infection. * Incapable to perform protocol visits. * Another neoplasia for the last 2 years (except squamous or basocellular skin cancer). * Hypersensitivity history to rapamycin analogs. * Chronic treatment with corticoids (except per oral, topical or local treatment) or another immunosuppressor agent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the Everolimus aim response in children and adolescents with refractory and relapsed Rhabdomyosarcoma and other soft tissue sarcomas | Up to 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Define Everolimus toxicity in this population | Up to 2 years |
Countries
Brazil
Contacts
Primary ContactSidnei Epelman, MD
Outcome results
None listed